Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies
1Department of Gastrointestinal Medical Oncology, University of Texas - MD Anderson Cancer Center, Houston, TX 77008.
Purpose Of Review:
This review seeks to detail the clinical and pathologic features specific to BRAF colorectal cancer. Application of novel preclinical findings translated into the clinic for the development of new therapeutic options for patients with BRAF metastatic colorectal cancer will be detailed.
Recent Findings:
While BRAF inhibitors in monotherapy do not have the same clinical activity for colorectal cancer relative to other solid tumors harboring an oncogenic BRAF mutation, combination approaches targeting BRAF + MEK +EGFR hold promise for patients BRAF colorectal cancer.
Summary:
Simultaneous targeting of multiple drivers along the MAPK pathway improve clinical outcomes for patients with BRAF colorectal cancer. Targeted therapies and immunotherapy hold great promise in the years to come for patients with this subtype of colorectal cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...